Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;199(4):433-434.
doi: 10.1007/s00408-021-00452-8. Epub 2021 May 25.

On Chronic Cough Diagnosis, Classification, and Treatment

Alyn Hugh Morice  1
Affiliations

On Chronic Cough Diagnosis, Classification, and Treatment

Alyn Hugh Morice. Lung. 2021 Aug.
No abstract available

PubMed Disclaimer

References

    1. Dicpinigaitis PV (2021) Coming soon: the first-ever drug(s) for refractory chronic cough. Lung 199(2):83–84 - DOI
    1. Morice AH, Birring SS, Smith JA, McGarvey LP, Schelfhout J, Martin Nguyen A, Xu ZJ, Wu WC, Muccino DR, Sher MR (2021) Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant. Lung 199(2):121–129 - DOI
    1. Park J-s, Burton L, Van der Wall H, Falk GL (2021) Modified reflux scintigraphy detects pulmonary microaspiration in severe gastro-esophageal and laryngopharyngeal reflux disease. Lung 199(2):139–145 - DOI
    1. Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM (2011) Cough hypersensitivity syndrome: a distinct clinical entity. Lung 189(1):73–79 - DOI
    1. McGarvey L, Birring S, Morice A, Dicpinigaitis P, Pavord I, Schelfhout J, Martin Nguyen A, Li Q, Tzontcheva A, Iskold B, Green S, La Rosa C, Muccino D, Smith J (2020) Late breaking abstract—two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2). Eur Respir J 56(suppl 64):3800

LinkOut - more resources